1. Home
  2. CDLR vs TRVI Comparison

CDLR vs TRVI Comparison

Compare CDLR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadeler AS

CDLR

Cadeler AS

N/A

Current Price

$24.88

Market Cap

2.5B

Sector

N/A

ML Signal

N/A

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

N/A

Current Price

$17.23

Market Cap

2.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CDLR
TRVI
Founded
2008
2011
Country
Denmark
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.6B
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
CDLR
TRVI
Price
$24.88
$17.23
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$21.55
AVG Volume (30 Days)
57.4K
1.4M
Earning Date
05-20-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.91
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$53.56
N/A
Revenue Next Year
$32.79
N/A
P/E Ratio
$7.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.37
$6.98
52 Week High
$30.01
$20.22

Technical Indicators

Market Signals
Indicator
CDLR
TRVI
Relative Strength Index (RSI) 59.88 41.56
Support Level $24.92 $16.24
Resistance Level $25.38 $19.30
Average True Range (ATR) 0.44 0.75
MACD 0.09 -0.19
Stochastic Oscillator 67.79 26.70

Price Performance

Historical Comparison
CDLR
TRVI

About CDLR Cadeler AS

Cadeler AS is an offshore wind installation vessel contractor. It currently operates various offshore jack-up wind installation vessels, with new builds on order. The Group operates within the market for the transportation and installation of offshore wind turbine generators (WTGs) and their foundations. In addition to wind farm installation, its vessels can perform maintenance, decommissioning, and other general construction tasks within the offshore industry. Cadler's customer base consists of offshore wind farm developers, original equipment manufacturers, and various offshore contractors. Geographically, the Group generates maximum revenue from the United States and the rest from the United Kingdom, Taiwan, Germany, Denmark, Poland, and other regions.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: